Neuroadaptive mechanisms of addiction: Studies on the extended amygdala

European Neuropsychopharmacology

Volumn 13, Issue 6, 2003, Pages 442-452

  Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Addiction; Allostasis; Amygdala; Cocaine; Corticotropin releasing factor; Ethanol; Reward

Indexed keywords

17 METHYLNALOXONE; 3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALCOHOL; AMPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; COCAINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR[12-41][DEXTRO PHENYLALANINE]; CORTICOTROPIN RELEASING FACTOR[9-41]; DOPAMINE; DRONABINOL; ECOPIPAM; GLUTAMIC ACID; MORPHINE; MUSCIMOL; NEUROTRANSMITTER; NICOTINE; OPIATE ANTAGONIST; OPIATE PEPTIDE; PROPRANOLOL; UNCLASSIFIED DRUG;

ADAPTATION; ADDICTION; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; AMYGDALOID NUCLEUS; ANXIETY; BRAIN FUNCTION; COCAINE DEPENDENCE; COMPULSION; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG USE; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; FOREBRAIN; HOMEOSTASIS; IMPULSE CONTROL DISORDER; MICROINJECTOR; MOTIVATION; NEUROANATOMY; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NONHUMAN; OBSESSION; PRIORITY JOURNAL; REINFORCEMENT; RELAPSE; REVIEW; REWARD; STRESS; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 0242467879     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2003.08.005     Document Type: Article

References (46)

1. Alheid G.F., De Olmos J.S., Beltramino C.A. Amygdala and extended amygdala. Paxinos G. The Rat Nervous System. 1995;495-578 Academic Press, San Diego.
2. Allen Y.S., Roberts G.W., Bloom S.R., Crow T.J., Polak J.M. Neuropeptide Y in the stria terminalis: evidence for an amygdalofugal projection. Brain Res. 321:1984;357-362.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
4. Bergman J., Kamien J.B., Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav. Pharmacol. 1:1990;355-363.
5. Caine S.B., Koob G.F. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav. Pharmacol. 6:1995;333-347.
6. Caine S.B., Heinrichs S.C., Coffin V.L., Koob G.F. Effects of the dopamine D1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res. 692:1995;47-56.
7. Delfs J.M., Zhu Y., Druhan J.P., Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature. 403:2000;430-434.
8. Diaz J., Lévesque D., Lammers C.H., Griffon N., Martres M.-P., Schwartz J.-C., Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
9. Dong H.W., Petrovich G.D., Swanson L.W. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res. Rev. 38:2001;192-246.
10. Epping-Jordan M.P., Markou A., Koob G.F. The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res. 784:1998;105-115.
11. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature. 393:1998;76-79.
12. Gardner E.L., Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 5:1998;502-533.
13. Gracy K.N., Dankiewicz L.A., Koob G.F. Opiate withdrawal-induced Fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology. 24:2001;152-160.
14. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides. 13:1992;451-460.
15. Heimer L., Alheid G. Piecing together the puzzle of basal forebrain anatomy. Napier T.C., Kalivas P.W., Hanin I. The Basal Forebrain: Anatomy to Function. Advances in Experimental Medicine and Biology. vol. 295:1991;1-42 Plenum, New York.
16. Heinrichs S.C., Menzaghi F., Schulteis G., Koob G.F., Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav. Pharmacol. 6:1995;74-80.
17. Heyser C.J., Roberts A.J., Schulteis G., Koob G.F. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol. Clin. Exp. Res. 23:1999;1468-1476.
18. Hyytia P., Koob G.F. GABA-A receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur. J. Pharmacol. 283:1995;151-159.
19. Koob G.F. Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
20. Koob G.F. Hedonic valence, dopamine, and motivation. Mol. Psychiatry. 1996;186-189.
21. Koob G.F. Alcoholism: allostasis and beyond. Alcohol. Clin. Exp. Res. 27:2003;232-243.
22. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
23. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 278:1997;52-58.
24. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 24:2001;97-129.
25. Koob G.F., Markou A., Weiss F., Schulteis G. Opponent process and drug dependence: neurobiological mechanisms. Semin. Neurosci. 5:1993;351-358.
26. Koob G.F., Heinrichs S.C., Menzaghi F., Pich E.M., Britton K.T. Corticotropin releasing factor, stress and behavior. Semin. Neurosci. 6:1994;221-229.
27. Koob G.F., Carrera M.R.A., Gold L.H., Heyser C.J., Maldonado-Irizarry C., Markou A., Parsons L.H., Roberts A.J., Schulteis G., Stinus L., Walker J.R., Weissenborn R., Weiss F. Substance dependence as a compulsive behavior. J. Psychopharmacol. 12:1998;39-48.
28. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron. 21:1998;467-476.
29. Kozicz T. Axon terminals containing tyrosine hydroxylase- and dopamine-beta-hydroxylase immunoreactivity form synapses with galanin immunoreactive neurons in the lateral division of the bed nucleus of the stria terminalis in the rat. Brain Res. 914:2001;23-33.
30. Markou A., Koob G.F. Post-cocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology. 4:1991;17-26.
31. McDonald A.J., Shammah-Lagnado S.J., Shi C., Davis M. Cortical afferents to the extended amygdala. McGinty J.F. Advancing from the Ventral Striatum to the Extended Amygdala: Implications for Neuropsychiatry and Drug Abuse. Annals of the New York Academy of Sciences. vol. 877:1999;309-338 New York Academy of Sciences, New York.
32. Merlo-Pich E., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 15:1995;5439-5447.
33. Olive M.F., Koenig H.N., Nannini M.A., Hodge C.W. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol. Biochem. Behav. 72:2002;213-220.
34. Paterson N.E., Myers C., Markou A. Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology. 152:2000;440-446.
35. Phelix C.F., Paull W.K. Demonstration of distinct corticotropin releasing factor-containing neuron populations in the bed nucleus of the stria terminalis: a light and electron microscopic immunocytochemical study in the rat. Histochemistry. 94:1990;345-364.
36. Pontieri F.E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 92:1995;12304-12308.
37. Rasmussen D.D., Boldt B.M., Bryant C.A., Mitton D.R., Larsen S.A., Wilkinson C.W. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol. Clin. Exp. Res. 24:2000;1836-1849.
38. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32.
39. Richter R.M., Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse. 32:1999;254-261.
40. Rivier C., Bruhn T., Vale W. Effect of ethanol on the hypothalamic-pituitary-adrenal axis in the rat: role of corticotropin-releasing factor (CRF). J. Pharmacol. Exp. Ther. 229:1984;127-131.
41. Roberts A.J., Cole M., Koob G.F. Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol. Clin. Exp. Res. 20:1996;1289-1298.
42. Russell M.A.H. What is dependence? Edwards G. Drugs and Drug Dependence. 1976;182-187 Lexington Books, Lexington, MA.
43. Schulteis G., Markou A., Gold L.H., Stinus L., Koob G.F. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J. Pharmacol. Exp. Ther. 271:1994;1391-1398.
44. Schulteis G., Markou A., Cole M., Koob G. Decreased brain reward produced by ethanol withdrawal. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5880-5884.
45. Solomon R.L., Corbit J.D. An opponent-process theory of motivation: 1. Temporal dynamics of affect. Psychol. Rev. 81:1974;119-145.
46. Valdez G.R., Roberts A.J., Chan K., Davis H., Brennan M., Zorrilla E.P., Koob G.F. Increased ethanol self-administration and anxiety-like behavior during acute withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol. Clin. Exp. Res. 26:2002;1494-1501.